Genetic Technologies Boosts Capital with Radium Loan
TipRanks (Tue, 26-Mar 8:57 AM ET)
GTG Global Collaborations and Innovation Update
Globe Newswire (Tue, 26-Mar 8:00 AM ET)
GENE to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare
Globe Newswire (Mon, 25-Mar 8:00 AM ET)
GTG to launch U.S. Customer Digital Media Sales Campaign
Globe Newswire (Wed, 28-Feb 8:00 AM ET)
Launching our most comprehensive test and expanding into new global markets
Globe Newswire (Wed, 31-Jan 8:00 AM ET)
Genetic Technologies Regains Compliance with Nasdaq Minimum Bid Price Requirement
Globe Newswire (Fri, 5-Jan 8:00 AM ET)
ACCESSWIRE (Fri, 29-Dec 9:01 AM ET)
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.
Genetic Technologies - American Depositary Shares trades on the NASDAQ stock market under the symbol GENE.
As of March 28, 2024, GENE stock price climbed to $2.89 with 15,653 million shares trading.
GENE has a beta of 0.57, meaning it tends to be less sensitive to market movements. GENE has a correlation of 0.01 to the broad based SPY ETF.
GENE has a market cap of $11.12 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, GENE stock traded as high as $28.70 and as low as $1.80.
GENE stock has underperformed the market in the last year with a return of -50.6%, while SPY returned +33.6%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in GENE shares. However, GENE has outperformed the market in the last 3 month and 2 week periods, returning +22.5% and +12.0%, while SPY returned +10.1% and +1.7%, respectively. This indicates GENE has been having a stronger performance recently.
GENE support price is $2.63 and resistance is $3.00 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GENE stock will trade within this expected range on the day.